Drug Application | Weeks PI | Avg. Sec. (±S.E.M.) | n | EAE Deficit Score Avg. Score (±S.E.M.) | ||||
---|---|---|---|---|---|---|---|---|
Region | Group | |||||||
A. Veratridine (100.0 μM) latency to peak in EAE and sham mice | ||||||||
Lumbar | Sham | 2 weeks PI | 501 (±31) | 20 | 0 | |||
3 weeks PI | 519 (±23) | 19 | 0 | |||||
4 weeks PI | 464 (±35) | 18 | 0 | |||||
5 weeks PI | 436 (±25) | 19 | 0 | |||||
Lumbar | EAE | 2 weeks PI | 411 (±30) | 21 | 2.6 (±0.2) | |||
3 weeks PI | 570 (±53) | 8 | 2.2 (±0.4) | |||||
4 weeks PI | 532 (±52) | 16 | 2.4 (±0.3) | |||||
5 weeks PI | 526 (±42) | 11 | 1.1 (±0.3) | |||||
B. Veratridine (100.0 μM) latency to peak in EAE and sham mice | ||||||||
Sacral | Sham | 2 weeks PI | 449 (±29) | 20 | 0 | |||
3 weeks PI | 453 (±18) | 19 | 0 | |||||
4 weeks PI | 478 (±28) | 20 | 0 | |||||
5 weeks PI | 451 (±16) | 19 | 0 | |||||
Sacral | EAE | 2 weeks PI | 458 (±32) | 16 | 2.5 (±0.2) | |||
3 weeks PI | 507 (±26) | 7 | 2.3 (±0.5) | |||||
4 weeks PI | 428 (±17) | 17 | 2.4 (±0.2) | |||||
|
|
| 532 (±41) | 13 | 1.2 (±0.3) |